ALPMY News and Press, Astellas Pharma Inc. ADR From 08/18/22

The U.S. Food and Drug Administration (FDA) accepted to review Astellas Pharma's ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) application seeking approval of fezolinetant to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. The FDA is expected to make ...

U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant PR Newswire If approved by the FDA, fezolinetant would be a nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause TOKYO , Aug. 18, 2022 /PRNewswir...

Merck  & Co.'s ( NYSE: MRK ) potential $40 billion acquisition of Seagen ( NASDAQ: SGEN ) is likely to be back in focus after the cancer drug maker had unfavorable outcome in its arbitration with the Japanese pharma Daiichi Sankyo ( OTCPK:DSKYF ). While ...

Astellas Announces Management Structure PR Newswire TOKYO , Aug. 2, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced the following changes to its management structure eff...

While the Tweedy, Browne Funds were not immune to the challenges during the quarter, they, for the most part, held up much better than their benchmark international and global indices. It is impossible, of course, to know whether markets have hit bottom, but if the past is prologue co...

Astellas Pharma, Inc. (ALPMF) Q1 2022 Earnings Conference Call August 01, 2022 03:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Minoru Kikuoka - CFO Yukio Matsui - CCO Bernie Zeiher - CMO Conference Call Particip...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Astellas Pharma Inc. 2022 Q1 - Results - Earnings Call Presentation

Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer PR Newswire – Companies plan to discuss results with regulatory authorit...

Japan's Astellas Pharma ( OTCPK:ALPMY ) ( OTCPK:ALPMF ) said it will invest $70M as it plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center. The 154K square-foot building at 480 Forbes Boulevard will...

Astellas Unveils Plans to Open New Biotech Campus in South San Francisco PR Newswire New 154,000-square-foot facility will provide a West Coast center with a focus on research, innovation, and commercial collaboration across corporate and program areas TOKYO ...